Thorough QT Study to Evaluate the Effects of BI 409306 as Single Dose on Cardiac Safety Parameters in Healthy Male and Female Subjects. A Randomized, Placebo Controlled, Double-blind, Five-period Crossover Study With (Open-label) Moxifloxacin as Positive Control
Latest Information Update: 14 Mar 2024
Price :
$35 *
At a glance
- Drugs Osoresnontrine (Primary)
- Indications Alzheimer's disease; Cognition disorders; Psychotic disorders; Schizophrenia
- Focus Adverse reactions
- Acronyms Thorough QT
- Sponsors Boehringer Ingelheim
- 16 Sep 2019 Status changed from active, no longer recruiting to completed.
- 23 Aug 2019 Planned End Date changed from 15 Aug 2019 to 29 Aug 2019.
- 23 Aug 2019 Planned primary completion date changed from 15 Aug 2019 to 29 Aug 2019.